| 000 | 01195 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250517024131.0 | ||
| 264 | 0 | _c20150831 | |
| 008 | 201508s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1002/cpt.129 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWagner, J A | |
| 245 | 0 | 0 |
_aImplications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cJul 2015 |
||
| 300 |
_a12-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aBiomarkers _xanalysis |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 |
_aEndpoint Determination _xmethods |
| 650 | 0 | 4 | _aGovernment Agencies |
| 650 | 0 | 4 | _aGuidelines as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 700 | 1 | _aBall, J R | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 98 _gno. 1 _gp. 12-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpt.129 _zAvailable from publisher's website |
| 999 |
_c24765427 _d24765427 |
||